WEST LAFAYETTE, IN / ACCESSWIRE / July 31, 2017 / Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company"), a
recognized global leader in the development of instrumentation for automated blood sampling in animal models, today announced that
it has entered into a reseller agreement with LABEX of MA ("LABEX") for refurbished BASi Culex® Automated Blood Sampling
Systems.
BASi Culex Automated Blood Sampling Systems deliver programmable, continuous, automated blood micro sampling that provides a
full pharmacokinetic curve from a single, fully conscious, freely-moving animal. The system allows for the simultaneous collection
of multiple data streams such as blood, bile, metabolites, dialysates and more. LABEX is a leading source of reconditioned and used
animal caging and vivarium equipment.
"We couldn't be more pleased to be partnering with LABEX as a reseller of our refurbished Culex systems given their industry
experience, a broad network of loyal customers, and exceptional client care," said Alan Loch, Director of Business Development for
BASi. "Our Culex systems perfectly complement LABEX's already incomparable array of high-quality, reconditioned and used vivarium
equipment."
Ed Russo, President of LABEX of MA said, "Everyone here at LABEX is excited about our recent partnership with BASi. We are
hopeful it will open many doors for us while we are able to help our customers purchase top-notch blood sampling systems."
About LABEX of MA
LABEX of MA brings together a unique combination of industry experience and unmatched inventory for providing the best choice
for reconditioned vivarium equipment. The Company's tremendous industry experience and broad network makes them uniquely qualified
to understand the needs and requirements of the university, research, pharmaceutical and biotechnology clients. Visit
www.labexofma.com for more about LABEX of MA.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's
leading drug development companies and medical research organizations. The Company focuses on developing innovative services and
products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more information
about BASi.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to,
risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and
sales of products and services, changes in technology, industry standards and regulatory standards, and various market and
operating risks detailed in the company's filings with the Securities and Exchange Commission.
Company Contact:
Jill Blumhoff Chief Financial Officer & Vice President of Finance Phone: 765.497.8381 jblumhoff@BASinc.com
SOURCE:
Bioanalytical Systems, Inc.
